SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Key Takeaways:

• Saqib Islam will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025.
• SpringWorks Therapeutics recently received FDA approval for OGSIVEO® (nirogacestat), their first therapy.
• The company focuses on precision medicine for severe rare diseases and cancer.
• SpringWorks has a diversified pipeline spanning solid tumors and hematological cancers.
• Collaborations with industry and academia enhance their research and development efforts.

CEO to Address 43rd Annual J.P. Morgan Healthcare Conference

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company, announced that Chief Executive Officer Saqib Islam will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Monday, January 13, 2025, at 11:15 a.m. Pacific Time.

To access the live webcast, interested parties are encouraged to visit the Events & Presentations page within the Investors & Media section of the company’s website at https://ir.springworkstx.com . A replay of the webcast will be available for a limited time following the conference.

Milestone Achievement with FDA Approval of OGSIVEO®

The presentation comes on the heels of a significant milestone for SpringWorks Therapeutics: the U.S. Food and Drug Administration’s approval of OGSIVEO® (nirogacestat). This therapy is approved for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. As the company’s first FDA-approved therapy, OGSIVEO® represents a pivotal advancement in addressing this severe rare disease.

Commitment to Rare Diseases and Cancer Treatments

SpringWorks Therapeutics applies a precision medicine approach to develop and deliver life-changing medicines for people with severe rare diseases and cancer. The company is dedicated to improving outcomes for patients who have limited or no treatment options. By focusing on targeted therapies, SpringWorks aims to address unmet medical needs in the healthcare landscape.

Expanding Pipeline and Collaborations

Beyond OGSIVEO®, SpringWorks has a diversified targeted therapy pipeline that spans solid tumors and hematological cancers. Their programs range from preclinical development to advanced clinical trials, highlighting the company’s robust growth potential. In addition to their wholly owned programs, SpringWorks has entered into multiple collaborations with innovators in industry and academia. These partnerships aim to unlock the full potential of their portfolio and create more solutions for patients in need.

Accessing the Presentation and Further Information

For those interested in learning more about SpringWorks Therapeutics and their ongoing projects, the upcoming presentation at the J.P. Morgan Healthcare Conference provides an invaluable opportunity. By tuning into the live webcast or accessing the replay, stakeholders can gain insights into the company’s recent achievements and future endeavors.

For additional information, visit www.springworkstx.com and follow @SpringWorksTx on X (formerly Twitter), LinkedIn, and YouTube.

Contacts:

Investors

investors@springworkstx.com

Media

media@springworkstx.com